Original Article| Volume 28, ISSUE 2, P468-475, March 2023

Protein tyrosine phosphatase non-receptor type 12 suppresses tumor progression in osteosarcoma cells

  • Xinwu Wang
    Department of Orthopaedics, The First Hospital of Putian City, Putian, Fujian, 351199, China
    Search for articles by this author
  • Xinwen Wang
    Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, China
    Search for articles by this author
  • Jiankun Lai
    Department of Orthopaedics, Dongguan People 's Hospital, Dongguan, Guangdong, 523059, China
    Search for articles by this author
  • Weifeng Xu
    Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, China
    Search for articles by this author
  • Wenxiong Zhu
    Corresponding author. Department of Orthopaedics, Dongguan People 's Hospital, 78# Wandao Road, Xinguyong Community, Wanjiang Street, Dongguan, Guangdong, 523059, China. Fax: +86 076928636300
    Department of Orthopaedics, Dongguan People 's Hospital, Dongguan, Guangdong, 523059, China
    Search for articles by this author
  • Guoxian Chen
    Corresponding author. Department of Orthopaedics, the First Hospital of Putian City, 389# Longdejing Community, Nanmen West Road, Chengxiang District, Putian, Fujian, 351199, China. Fax: +86 05942280617
    Department of Orthopaedics, The First Hospital of Putian City, Putian, Fujian, 351199, China
    Search for articles by this author



      Protein tyrosine phosphatase non-receptor 12 (PTPN12) plays a prominent role in various cancers as a tumor suppressor. However, the expression of PTPN12 and its biological functions in osteosarcoma (OS) remains to be determined.


      PTPN12 expression in OS was explored in public databases and detected by immunohistochemistry and Western blot. The cell viability was determined by Cell Counting Kit-8 (CCK-8) assay and colony formation. The cell migration and invasion were assessed by the Transwell assay. Flow cytometry analysis was applied to detect cell apoptosis and cell cycle distribution. To investigate the related mechanism, the levels of EGFR and downstream proteins were detected by Western blot.


      PTPN12 expression was significantly decreased in OS samples in GEO database and our hospital. OS cell lines in Cancer Cell Line Encyclopedia (CCLE) database and our cultured OS cells also demonstrated low PTPN12 expression. Lentivirus-induced overexpression of PTPN12 significantly inhibited the cell viability, migration and invasion of 143B and U2OS cells. The results of flow cytometry found that PTPN12 overexpression promoted cell apoptosis and induced cell cycle arrest at G1 phase in 143B and U2OS cells. The phosphorylation levels of EGFR and subsequent proteins of the PI3K/AKT and ERK pathways were inactivated as a result of PTPN12 overexpression in OS.


      PTPN12 plays a tumor suppressive role in OS cells. Restoring of PTPN12 activity may provide new insights for the treatment of this disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Orthopaedic Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Whelan J.S.
        • Davis L.E.
        Osteosarcoma, chondrosarcoma, and chordoma.
        J Clin Oncol. 2018 Jan 10; 36: 188-193
        • Isakoff M.S.
        • Bielack S.S.
        • Meltzer P.
        • Gorlick R.
        Osteosarcoma: current treatment and a collaborative pathway to success.
        J Clin Oncol. 2015 Sep 20; 33: 3029-3035
        • Kansara M.
        • Teng M.W.
        • Smyth M.J.
        • Thomas D.M.
        Translational biology of osteosarcoma.
        Nat Rev Cancer. 2014 Nov; 14: 722-735
        • Frankson R.
        • Yu Z.H.
        • Bai Y.
        • Li Q.
        • Zhang R.Y.
        • Zhang Z.Y.
        Therapeutic targeting of oncogenic tyrosine phosphatases.
        Cancer Res. 2017 Nov 1; 77: 5701-5705
        • Shalev M.
        • Elson A.
        The roles of protein tyrosine phosphatases in bone-resorbing osteoclasts.
        Biochim Biophys Acta Mol Cell Res. 2019 Jan; 1866: 114-123
        • Mansour M.
        • Nievergall E.
        • Gegenbauer K.
        • Llerena C.
        • Atapattu L.
        • Hallé M.
        • et al.
        PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling.
        J Cell Sci. 2016 Jan 15; 129: 277-289
        • de Voer R.M.
        • Hahn M.M.
        • Weren R.D.
        • Mensenkamp A.R.
        • Gilissen C.
        • van Zelst-Stams W.A.
        • et al.
        Identification of novel candidate genes for early-onset colorectal cancer susceptibility.
        PLoS Genet. 2016 Feb; 12e1005880
        • Cao X.
        • Li Y.
        • Luo R.Z.
        • He L.R.
        • Yang J.
        • Zeng M.S.
        • et al.
        Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
        Ann Thorac Surg. 2012 May; 93: 1674-1680
        • Su Z.
        • Tian H.
        • Song H.Q.
        • Zhang R.
        • Deng A.M.
        • Liu H.W.
        PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
        Med Oncol. 2013; 30: 618
        • Xunyi Y.
        • Zhentao Y.
        • Dandan J.
        • Funian L.
        Clinicopathological significance of PTPN12 expression in human breast cancer.
        Braz J Med Biol Res. 2012 Dec; 45: 1334-1340
        • Piao Y.
        • Liu X.
        • Lin Z.
        • Jin Z.
        • Jin X.
        • Yuan K.
        • et al.
        Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
        Oncol Lett. 2015 Sep; 10: 1620-1626
        • Luo R.Z.
        • Cai P.Q.
        • Li M.
        • Fu J.
        • Zhang Z.Y.
        • Chen J.W.
        • et al.
        Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.
        PLoS One. 2014 Jan 24; 9e85592
        • Cao X.
        • Chen Y.Z.
        • Luo R.Z.
        • Zhang L.
        • Zhang S.L.
        • Zeng J.
        • et al.
        Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
        Oncotarget. 2015 May 10; 6: 11704-11713
        • Li H.
        • Yang F.
        • Liu C.
        • Xiao P.
        • Xu Y.
        • Liang Z.
        • et al.
        Crystal structure and substrate specificity of PTPN12.
        Cell Rep. 2016 May 10; 15: 1345-1358
        • Nair A.
        • Chung H.C.
        • Sun T.
        • Tyagi S.
        • Dobrolecki L.E.
        • Dominguez-Vidana R.
        • et al.
        Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
        Nat Med. 2018 May; 24: 505-511
        • Zhang D.
        • Cui G.
        • Sun C.
        • Lei L.
        • Lei L.
        • Williamson R.A.
        • et al.
        Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-β axis.
        Biochem Biophys Res Commun. 2019 Apr 30; 512: 360-366
        • McCleese J.K.
        • Bear M.D.
        • Kulp S.K.
        • Mazcko C.
        • Khanna C.
        • London C.A.
        Met interacts with EGFR and Ron in canine osteosarcoma.
        Vet Comp Oncol. 2013 Jun; 11: 124-139
        • Wu X.
        • Yan L.
        • Liu Y.
        • Xian W.
        • Wang L.
        • Ding X.
        MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7.
        PLoS One. 2017 Jun 12; 12e0175553
        • Barretina J.
        • Caponigro G.
        • Stransky N.
        • Venkatesan K.
        • Margolin A.A.
        • Kim S.
        • et al.
        The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
        Nature. 2012 Mar 28; 483: 603-607
        • Sun T.
        • Aceto N.
        • Meerbrey K.L.
        • Kessler J.D.
        • Zhou C.
        • Migliaccio I.
        • et al.
        Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.
        Cell. 2011 Mar 4; 144: 703-718
        • Piao Y.R.
        • Jin Z.H.
        Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
        J buon. 2015 Sep-Oct; 20: 1258-1266
        • Li J.
        • Davidson D.
        • Martins Souza C.
        • Zhong M.C.
        • Wu N.
        • Park M.
        • et al.
        Loss of PTPN12 stimulates progression of ErbB2-dependent breast cancer by enhancing cell survival, migration, and epithelial-to-mesenchymal transition.
        Mol Cell Biol. 2015 Dec; 35: 4069-4082
        • Lin Q.
        • Wang H.
        • Lin X.
        • Zhang W.
        • Huang S.
        • Zheng Y.
        PTPN12 affects nasopharyngeal carcinoma cell proliferation and migration through regulating EGFR.
        Cancer Biother Radiopharm. 2018 Mar; 33: 60-64
        • Thummuri D.
        • Kumar S.
        • Surapaneni S.K.
        • Tikoo K.
        Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer.
        Life Sci. 2015 Jun 1; 130: 73-80
        • Espejo R.
        • Jeng Y.
        • Paulucci-Holthauzen A.
        • Rengifo-Cam W.
        • Honkus K.
        • Anastasiadis P.Z.
        • et al.
        PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity.
        J Cell Sci. 2014 Feb 1; 127: 497-508
        • Mandarini E.
        • Tollapi E.
        • Zanchi M.
        • Depau L.
        • Pini A.
        • Brunetti J.
        • et al.
        Endocytosis and trafficking of heparan sulfate proteoglycans in triple-negative breast cancer cells unraveled with a polycationic peptide.
        Int J Mol Sci. 2020 Nov 5; 21: 8282
        • Zheng Y.
        • Zhang C.
        • Croucher D.R.
        • Soliman M.A.
        • St-Denis N.
        • Pasculescu A.
        • et al.
        Temporal regulation of EGF signalling networks by the scaffold protein Shc1.
        Nature. 2013 Jul 11; 499: 166-171
        • De Robertis M.
        • Loiacono L.
        • Fusilli C.
        • Poeta M.L.
        • Mazza T.
        • Sanchez M.
        • et al.
        Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer.
        Clin Cancer Res. 2017 Jan 1; 23: 159-170
        • Lee K.J.
        • Kim Y.
        • Yoo Y.H.
        • Kim M.S.
        • Lee S.H.
        • Kim C.G.
        • et al.
        CD99-Derived agonist ligands inhibit fibronectin-induced activation of β1 integrin through the protein kinase A/SHP2/extracellular signal-regulated kinase/PTPN12/focal adhesion kinase signaling pathway.
        Mol Cell Biol. 2017 Jul 15; 37e00675-16
        • Villa-Moruzzi E.
        PTPN12 controls PTEN and the AKT signalling to FAK and HER2 in migrating ovarian cancer cells.
        Mol Cell Biochem. 2013 Mar; 375: 151-157